

GLAXOSMITHKLINE PLC

Form 6-K

July 31, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 2013

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in interests in the American Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the under-mentioned Person Discharging Managerial Responsibility (PDMR) on 31 July 2013:-

| PDMR        | GSK Share Option Plan   |
|-------------|---|
| Mr W C Louv | Exercise of option over 2,276 ADSs, granted on 28 October 2003 under the GlaxoSmithKline Share Option Plan at a price of \$43.92 per ADS, and sale of 2,276 ADSs at a price of \$51.137 per ADS.<br><br>Exercise of option over 22,724 ADSs, granted on 28 October 2003 under the GlaxoSmithKline Share Option Plan at a price of \$43.92 per ADS, and sale of 22,724 ADSs at a price of \$51.15 per ADS. |

The Company and the above-mentioned person were advised of this information on 31 July 2013.

This notification relates to transactions notified in accordance with Disclosure Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

31 July 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 31, 2013

By: VICTORIA WHYTE  
-----

Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc